Keywords
How to Cite
Abstract
Introduction: Today more than ever human health has been compromised; humanity is suffering from the invasion of the SARS-CoV-2 coronavirus, which has exposed the world to the worst health emergency in this century. Although the scientific community and global health systems are joining efforts in the search for a definitive treatment, to date it is recognized that the therapy is aimed at mitigating the symptoms. Objective: Identify scientific evidence on pharmacological treatment for patients with COVID-19. Methodology: An integrative review of literature published from December 2019 to October 2020, in the following information systems Clinical Key, Dialnet, EBSCO Host and Scopus was performed using the descriptors Coronavirus Infections, COVID-19, Drug therapy, and pharmacological treatment. The selection criteria were quantitative research articles of any type of design, in English and Spanish, available in full text, obtaining a sample of 24 articles. Results: Most of the studies were integrative reviews with a percentage of 66.6 and clinical or in vitro trials with a percentage of 12.5. Nine drugs of major use in COVID-19 were identified in the drug therapy, that is, Hydroxychloroquine/Chloroquine, Lopinavir/Ritonavir, Remdesivir, Azithromycin, Ivermectin, Tocilizumab and Dexamethasone. However, According to the scientific evidence only four drugs showed significant effectiveness. Conclusions: Remdesivir demonstrated greater effectiveness and safety during the treatment, and Tocilizumab and Dexamethasone showed favorable results. Nevertheless, the results are not conclusive. The authors pointed out that so far is not possible to conclude there are treatments that effectively fight COVID-19.
References
Organización para la Cooperación y el Desarrollo Económico [(OECD/The World Bank, 2020), Health at a Glance: Latin America and the Caribbean 2020 [Internet]. OECD Publishing, Paris; 2020 [citado 30 oct 2020]. Disponible en: https://doi.org/10.1787/6089164f-en
Organización Mundial de la Salud. Aceleración de la propagación de la COVID-19. [Internet]. OMS [Actualizado 30 oct 2020; citado 30 oct 2020]. Disponible en: https://www.who.int/es/news/item/30-10-2020-as-covid-19-spread-accelerates-ihr-emergency-committee-urges-focus-on-measures-that-work
World Health Organization (WHO). Statement on the fifth meeting of the International Health Regulations, 2005. Emergency Committee regarding the coronavirus disease (COVID-19) pandemic [Internet]. WHO, 2005 [Actualizado día 30 oct. 2020; citado día 30 oct 2020]. Disponible en: https://www.who.int/news/item/30-10-2020-statement-on-the-fifth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
Shankar A, Dubey A, Saini D, Prakash Ch. Role of complementary an alternative medicine in prevention and treatment of COVID-19: An overhyped hope. Chin J Integr Med [Internet]. 2020 [citado 30 oct 2020];26(8):565-567. Disponible en: https://doi.org/10.1007/s11655-020-2851-y
Crespillo C, Moreno S. Abordaje terapéutico en pacientes con infección por coronavirus SAR-COV-2. Act. Farm Terap [Internet]. 2020 [citado 30 oct 2020];18(2):109-120. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=7487153
Helmy Y, Fawzy M, Elaswad A, Sobieh A, Kenney S, Shehata A. The COVID-19 Pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment and control. J. Clin. Med [Internet]. 2020 [citado 30 oct 2020] 9:1225:1-29. Disponible en: https://doi.org/10.3390/jcm9041225
Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J of Pharmacol [Internet]. 2020 [citado 28 ago 2020];886:1-11. Disponible en: https://doi.org/10.1016/j.ejphar.2020.173451
Organización Mundial de la Salud. Manejo clínico de la COVID-19. Orientaciones provisionales [Internet]. OMS, 2019 [citado 30 oct 2020]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/332638/WHO-2019-nCoV-clinical-2020.5-spa.pdf
Santillán A, Palacios E. Actualización en el tratamiento de COVID-19. Archivos Venezolanos de Farmacología y Terapéutica [Internet]. 2020 [citado 30 oct 2020];39(2):191-194. Disponible en: https://www.revistaavft.com/images/revistas/2020/avft_2_2020/8_actualizacion.pdf
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 -2 infection in vitro. Cell Discov [Internet]. 2020 [citado 30 oct 2020];6(16):1-4. Disponible en: https://doi.org/10.1038/s41421-020-0156-0
Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an open-label non-randomized clinical trial, Francia. Int J Antimicrob Agents [Internet]. 2020 [citado 30 oct. 2020];56(1):1-6. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105949
Poschet J, Perkett E, Timmins G, Vojo Deretic. Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells. Preprints from mesdRxiv and bioRxiv [Internet]. 2020 [citado 30 oct 2020];3(29):1-21. Disponible en: https://doi.org/10.1101/2020.03.29.008631
Caly L, Druce J, Catton M, Jans D, Wagstaff K. The FDA approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res [Internet]. 2020 [citado 30 oct 2020];10(4):787. Disponible en: https://doi.org/10.1016/j.antiviral.2020.104787
Choudhary R, Sharma AK. Potential Use of Hydroxychloroquine, Ivermectin, and Azithromycin Drugs in the Fight Against COVID-19: Trends, Scope, and Relevance. New Microbes and New Infect [Internet]. 2020 [citado 30 oct 2020];1(35):1-4. Disponible en: https://www.clinicalkey.es/#!/content/journal/1-s2.0-S2052297520300366
Agencia Española de Medicamentos y Productos Sanitarios. Tratamientos disponibles sujetos a condiciones especiales de acceso para el manejo de la infección respiratoria por SARS CoV-2 [Internet]. España; 2020 [citado 30 oct 2020]. Disponible en: https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%e2%80%9119/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-SARS-CoV-2 -2/
Wayah S, Auta R, Waziri P, Haruna E. New insights on potential therapeutic options and vaccines for coronavirus disease-2019. Reviews in Medical Microbiology [Internet]. 2020 [citado 30 oct 2020];0(0):1-8. Disponible en: https://journals.lww.com/revmedmicrobiol/Citation/2021/04000/New_insights_on_potential_therapeutic_options_and.1.aspx
Benavides V. Reposicionamiento de medicamentos para COVID - 19. Universidad del Valle, Facultad de Salud, Escuela de Ciencias Básicas. Colomb Med (Cali) [Internet]. 2020 [citado 30 oct 2020];50(3):1-11. Disponible en: http://doi.org/10.25100/cm.v51i2.4279
Grove SK, Gray JR. Investigación en enfermería. Desarrollo de la práctica enfermera basada en la evidencia. 7 ed. España: Elsevier; 2019.
Guevara-Valtier M, Cárdenas-Villarreal V, Hernández-Cortes P. Protocolos de investigación en Enfermería. México: Manual Moderno; 2017.
Descriptores en Ciencias de la Salud. Biblioteca Virtual en Salud [Internet]. Organización Panamericana de la Salud; 2021 [citado 30 oct 2020]. Disponible en: http://decs2020.bvsalud.org/cgi-bin/wxis1660.exe/decsserver/
Medical Subject Heading [Internet]. National Library of Medecine. MesH, NIH; 2021 [citado 30 oct 2021]. Disponible en: https://www.ncbi.nlm.nih.gov/mesh/2050325
Fan L, Jiang, S, Yang X, Wang Z. COVID-19 Drug Treatment in China. Curr Pharmacol Reports [Internet]. 2020 [citado 30 oct 2020];6:146–154. Disponible en: https://doi.org/10.1007/s40495-020-00218-5
Tzu-Han Y, Chian-Ying C, Yi-Fan Y, Chian-Shiu C, Aliaksandr AY, Tzu-Ying Y, et al. Systematic review and meta-analysis of the effectiveness and safety of hidroxychloroquine in treating Covid-19 patients. J Chin Med Assoc [Internet]. 2020 [citado 30 oct 2020];10(1):1-31. Disponible en: https://doi.org/10.1097/jcma.0000000000000425
Tlayjeh H, Mhish OH, Enani MA, Alruwaili A, Tleyjeh R, Thalib L, et al. Association of corticosteroid use and outcomes in COVID-19 patients: a systematic review and meta-analysis. J Infect Public Heal [Internet]. 2020 [citado 30 oct 2020];13(11):1652-1663. Disponible en: https://www.clinicalkey.es/#!/content/journal/1-s2.0-S1876034120306638
Marto N, Monteiro E. Medicines for the treatment of COVID-19: Awaiting the evidence. Acta Med Port [Internet]. 2020 [citado 30 oct 2020];33(7-8):500-504. Disponible en: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/13908/5961
Reina J. Remdesivir, la esperanza antiviral frente al SARS-CoV-2. Rev. Esp. Quimioter [Internet]. 2020. [citado 30 oct 2020];33(3):176-179.Disponible en: https://seq.es/wp-content/uploads/2020/04/reina01apr2020.pdf
Díaz E, Amezaga- Menéndez R, Vidal-Cortés P, Escapa MG, Subeviola B, Serrano-Lázaro A, et al. Tratamiento farmacológico de la COVID-19: revisión narrativa de los grupos de trabajo de enfermedades infecciosas y sepsis (GTEIS) y del grupo de trabajo de transfusiones hemoderivados (GTTH). Med. Intensiva [Internet]. 2020 [citado 02 nov 2020];45(2):104-121. Disponible en: https://doi.org/10.1016/j.medin.2020.06.017
Gonzales-Zamora J, Quiroz T, Vega A. Tratamiento exitoso con remdesivir y corticoides en un paciente con neumonía asociada a COVID-19: reporte de un caso. Medwave [Internet]. 2020. [citado 30 oct 2020];20(7):e7998. Disponible en: https://www.medwave.cl/link.cgi/Medwave/Estudios/Casos/7998.act.
Organización Panamericana de la Salud. Recomendación sobre uso de ivermectina en el tratamiento de COVID-19. OPS [Internet]. 2020 [citado 30 oct 2020]. Disponible en:
https://docs.bvsalud.org/biblioref/2020/06/1100598/ops-tratamiento-ivermectina-junio-22-2020.pdf
Cao B, Wang D, Liu Wen, Wang J, Fan J, Ruan L, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N Engl J Med [Internet]. 2020 [citado 30 oct 2020];382:1787-1799. Disponible en: https://www.nejm.org/doi/10.1056/NEJMoa2001282
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA [Internet].2020. [citado 30 oct 2020];323(18):1824-1836. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32282022/.
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA [Internet]. 2020 [citado 30 oct 2020];323(24):2493-2502. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2766117
Spinner CD, Gottlieb RL, Criner GJ, Arribas JR, Cattelan AM, Soriano VA, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. JAMA [Internet]. 2020 [citado 30 oct 2020];324(11):1048-1057. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2769871
Jimbo-Sotomayor R, Gómez-Jaramillo AB, Sánchez X, Moreno-Piedrahita F. Ivermectina para el tratamiento de la infección COVID-19. Pontificia Universidad Católica del Ecuador [Internet]. 2020 [citado 20 oct 2020]. Disponible en: https://puceapex.puce.edu.ec/web/covid19-medidas-preventivas/wp-content/uploads/sites/6/2020/04/ivermectina.pdf
Huamán-Sánchez K. Efectividad y seguridad tocilizumab en el tratamiento de COVID-19. Unidad de Análisis y Generación de Evidencias en Salud Pública. Centro Nacional de Salud Pública. Serie síntesis de evidencias COVID-19 [Internet]. Perú; 2020 [citado 30 oct 2020]. Disponible en: https://web.ins.gob.pe/sites/default/files/Archivos/authenticated%2C%20administrator%2C%20editor/publicaciones/2020-08-04/SE_23%20Tocilizumab%20Covid-19.pdf
Pareja A, Luque JC. Alternativas terapéuticas farmacológicas para COVID-19. Horiz. Med (Lima) [Internet]. 2020 [citado 30 oct 2020];20(2):e1216. Disponible en: http://www.scielo.org.pe/pdf/hm/v20n2/1727-558X-hm-20-02-e1216.pdf
Moneriz C, Castro-Salguedo C. Fármacos prometedores y potenciales para el tratamiento de COVID-19. Revista Chilena de Infectología [Internet]. 2020 [citado 30 oct 2020];37(3):205-215. Disponible en: https://www.revinf.cl/index.php/revinf/article/view/728/397
Gómez-Tejeda JJ, Dieguez-Guach RA, Pérez-Abreu MR. Alternativas terapéuticas para el manejo de COVID - 19. Rev Habanera Cienc. Médi [Internet]. 2020 [citado 30 oct 2020]; 19 (Supl):e3328. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3328
Santos-Sánchez NF, Salas-Coronado R. Origen, características estructurales, medidas de prevención, diagnóstico y fármacos potenciales para prevenir y controlar COVID-19. Med Wave. [Internet]. 2020 [citado 30 oct 2020];20(8):1-28. Disponible en: https://www.medwave.cl/link.cgi/Medwave/Revisiones/RevisionClinica/8037.act
Joo M, Kang M, Youn S, Noh J, Cheong H, Kim W, Jung J. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study. J. Glob. Infect. Dis [Internet]. 2020 [citado 30 oct 2020];102: 275-281. Disponible en: https://doi.org/10.1016/j.ijid.2020.10.062
Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown A, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun [Internet]. 2020 [citado 30 oct 2020];11(222):1-14. Disponible en: https://doi.org/10.1038/s41467-019-13940-6
Secretaría de Salud. Propuesta de medicamentos para el tratamiento de COVID-19. Subsecretaría de Integración y Desarrollo del Sector Salud. Dirección General de Planeación y Desarrollo en Salud [Internet]. México; 2020 [citado 30 oct 2020]. Disponible en: http://www.sidss.salud.gob.mx/site2/docs/Propuesta_tratamiento_COVID19.pdf
Cepelowicz R, Sherman M, Fatteh N, Vogel F, Sacks J, Rajter J. Use of Ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ICON Study. Chest Infections [Internet]. 2020 [citado 30 oct 2020]. Article in press. Disponible en: https://doi.org/10.1016/j.chest.2020.10.009
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2021